Avineuro develops its research platform through strategic partnerships with highly acclaimed medical research institutions and reputable contract research organizations. Our business strategy involves in-licensing of clinically enabled compounds, partnering with pharma and biotech companies for co-development and other forms of collaboration.

OUR PARTNERSHIPS

CHEMDIV, INC.

Avineuro holds an exclusive licensing agreement with ChemDiv for drug candidates for treatment of multiple psychiatric and neurological indications.

DRUGS TECHNOLOGY and CHEMDIV, INC.

Avineuro has formed the broad research Partnership with ChemDiv and Drugs Technology for development and registration of its preclinical lead molecules for treatment of neurological and psychiatric diseases.

THE NATIONAL CENTER OF MENTAL HEALTH

In 2008 Avineuro announced the formation of a partnership with The National Center of Mental Health at Russian Academy of Medical Science for the development of Proof-of-Concept product candidates for treatment of anxiety, schizophrenia and Alzheimer’s disease.